ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0332

Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)

Yoshiyuki Arinuma1, Yasuhiro Hasegawa2, Yu Matsueda2, Kenji Oku3 and Kunihiro Yamaoka4, 1Kitasato University, Kanagawa, Japan, 2Kitasato University School of Medicine, Sagamihara, Japan, 3Kitasato University, Chigasaki, Japan, 4Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

Meeting: ACR Convergence 2022

Keywords: neuropsychiatric disorders, Neuropsychiatry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Microglial activation is critical for behavioral abnormalities in a mouse model of diffuse NPSLE following anti-glutamate receptor subunit GluN2 antibody (anti-GluN2) exposure to neurons. Recently, sTREM2 is known to be the specific activation marker for microglia. The aim of this study is to investigate the potential role of sTREM2 as a factor associating microglial activation with the complication of diffuse NPSLE in patients with SLE.

Methods: Patients with SLE who had collocated NPSLE admitted to our hospital were collected. sTREM2 in serum and cerebrospinal fluid (CSF) were measured by ELISA. Anti-GluN2 was also measured by in house ELISA. Patients and clinical information were collected from medical records. We retrospectively evaluated sTREM2 by NPSLE phenotypes and analyzed the relationship of sTREM2 and anti-GluN2 between diffuse NPSLE and focal neurological manifestations of NPSLE (focal NPSLE).

Results: Twenty-seven patients with diffuse NPSLE and 13 patients with focal NPSLE were recruited in this study. There was no significant difference in serum (p=0.367) and CSF sTREM2 (p=0.936) levels between diffuse and focal NPSLE. Of patients with diffuse NPSLE, CSF sTREM2 in patients with acute confusional state (ACS), the severest form of the diffuse NPSLE was significantly higher (median: 77.6, 0–3328.3 pg/mL) than those without ACS (0, 0–212.1 ng/mL) (p=0.0367) (Figure A). There was no correlation between serum and CSF sTREM2 in patients with diffuse NPSLE (r=0.0887, p=0.660). In addition, sTREM2 index showing the specific presence of sTREM2 in the central nervous system was also significantly elevated in patients with ACS (p=0.023), compared to those without ACS. Remarkably, the CSF sTREM2 levels were significantly correlated with the CSF anti-GluN2 titers (r=0.464, p=0.0394) (Figure B) in patients with diffuse NPSLE, but were not in those with focal NPSLE (r=0.-0584, p=0.876).

Conclusion: The correlation of sTREM2 and anti-GluN2 in CSF from patients with diffuse NPSLE implies that microglia activation is potentially induced after anti-GluN2 exposure in the central nervous system even in humans with diffuse NPSLE.

Supporting image 1

Figure1 sTREM2 levels and the correlation of anti-GluN2 antibody in patients with diffuse NPSLE


Disclosures: Y. Arinuma, None; Y. Hasegawa, None; Y. Matsueda, None; K. Oku, None; K. Yamaoka, AbbVie GK, Astellas, BMS, Chugai, Mitsubishi-Tanabe, Pfizer, Takeda.

To cite this abstract in AMA style:

Arinuma Y, Hasegawa Y, Matsueda Y, Oku K, Yamaoka K. Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/soluble-triggering-receptor-expressed-on-myeloid-cells-2-strem2-in-cerebrospinal-fluid-relating-to-development-of-diffuse-psychiatric-neuropsychological-syndromes-in-patients-with-systemic-lupus-ery/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/soluble-triggering-receptor-expressed-on-myeloid-cells-2-strem2-in-cerebrospinal-fluid-relating-to-development-of-diffuse-psychiatric-neuropsychological-syndromes-in-patients-with-systemic-lupus-ery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology